Authors: Jade Parker, Editor
A multi-institutional group of researchers have presented initial clinical results from a first-in-human study of E7046 in patients with cancers having high-myeloid cell infiltration. The findings were presented recently at the 2018 ASCO-SITC Clinical Immuno-Oncology Symposium (25–27 January, CA, USA).
E7046 is a potent, highly selective small-molecule inhibitor of PGE2-receptor type 4. Preclinical data have demonstrated that it reverses PGE2-mediated tumor immune suppression.